Analysts: Merck’s Gardasil undervalued by billions of dollars
Wolfe Research analysts say the market is underestimating the vaccine’s potential by more than $2 billion.
Sales
5 Steps to Successful Key Account Management
The healthcare ecosystem is changing rapidly to succeed requires the adoption of key account management (KAM), a systematic, robust alternative to the traditional buyer/seller model.
GlaxoSmithKline faces more Avandia fallout
GlaxoSmithKline is in Congressional crosshairs over its marketing of Avandia, and investors arent happy either.
AMA hooks up online with Sermo
The American Medical Association announced it is partnering with Sermo, the online community for physicians.
LLNS rebrands as LyonHeart
Lyons Lavey Nickel Swift is rebranding as “LyonHeart” under its proprietary creative-strategic process dubbed “Disruption.”
Nexavar also seen as liver cancer breakthrough
Onyx and Bayers kidney cancer drug Nexavar (sorafenib) was also found to extend the lives of liver cancer patients in a clinical trial by almost three months, or 44%, doctors said.
InVentiv buys brand ID shop Addison Whitney
InVentiv Health has acquired brand identity shop Addison Whitney.
Panel to review Sanofi-Aventis’ Ketek
The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).
Panel to review Sanofi-Aventis’ Ketek
The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).
AHA forbids Pfizer from presenting torcetrapib results
Pfizer won’t be allowed to present new data on its closely watched developmental drug torcetrapib at the annual American Heart Association (AHA) meeting this week.
Want to read more?
Please login or register first to view this content.
